Xeris Biopharma Holdings, Inc.
XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodicā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.47
Price-4.91%
-$0.38
1Y
Price
Market Cap
$1.239b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+14.9%
EBITDA Margin+0.8%
Net Profit Margin+24.3%
Free Cash Flow Margin+14.9%
EBITDA Margin+0.8%
Net Profit Margin+24.3%
Free Cash Flow MarginRevenue
$266.137m
+31.1%
1y CAGR+34.5%
3y CAGR+56.5%
5y CAGREarnings
-$15.640m
+71.5%
1y CAGR+39.2%
3y CAGR+35.1%
5y CAGREPS
-$0.10
+73.0%
1y CAGR+42.2%
3y CAGR+45.3%
5y CAGRBook Value
-$861k
$370.191m
Assets$371.052m
Liabilities$38.185m
DebtDebt to Assets
10.3%
1.4x
Debt to EBITDAFree Cash Flow
$19.824m
+152.4%
1y CAGR+76.0%
3y CAGR+57.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company